Exit Strategies for Life Sciences Investors in Kenya: M&A, IPO and Trade Sale Compared

Exit strategies for life sciences investors in Kenya rarely follow a single template. A private equity fund, venture investor or strategic partner that backed a Kenyan health-tech platform, diagnostics chain, pharmaceutical distributor or medical device company usually has three realistic routes out: a trade sale to a strategic acquirer, a listing on the Nairobi Securities Exchange, or a secondary sale or buyback. Each carries different deal mechanics, clearances and tax consequences, and the sector’s licensing regime adds a wrinkle ordinary exits do not face. This article compares the three routes and the tax and exchange control issues an investor should plan for before a term sheet is signed.

Trade Sale and M&A Exit: Strategic Acquirers, CAK Clearance and Licence Transfer

A trade sale to a multinational pharmaceutical group, regional healthcare consolidator or strategic operator is the most common and usually fastest exit route once a buyer is found. It is normally engineered through drag-along rights, compelling minority shareholders to sell alongside a majority seller once an agreed threshold accepts a bona fide offer, and tag-along rights, letting minority holders sell on the same terms if a majority shareholder sells first. Well-drafted agreements fix the drag threshold, notice period and price protection clearly, since a vague clause is a common source of dispute when an exit arrives.

Where the target’s turnover or assets are significant, the deal may require CAK notification before completion. Under CAK’s Consolidated Merger Guidelines, a healthcare-sector merger needs mandatory notification where combined turnover or assets reach at least KES 500 million and the target’s turnover exceeds KES 50 million, well below the general-economy figure of KES 1 billion combined with a target turnover above KES 100 million. Deals between KES 50 million and KES 500 million in healthcare are excluded. A merger implemented without required approval has no legal effect, so clearance is typically a condition precedent.

The sharpest structuring issue is that sector licences are generally not freely transferable on a change of control. A Pharmacy and Poisons Board (PPB) premises licence requires the Board to be notified in writing at least 30 days before any change of ownership, including a change in shareholding or directors, and renewal is reassessed against current conditions rather than granted automatically. A change of ownership of a Kenya Medical Practitioners and Dentists Council (KMPDC) facility similarly triggers a formal review first. Licence transfer consent belongs among the conditions precedent, not an assumption. Our guide to healthcare M&A due diligence covers this further.

IPO Exit on the Nairobi Securities Exchange: MIMS Versus GEMS

A public listing is the least common exit route today, since few Kenyan life sciences companies have reached the scale the Nairobi Securities Exchange’s (NSE) main board requires. The Main Investment Market Segment (MIMS) needs at least five years of operating history, three years of IFRS-compliant audited financials, minimum paid-up share capital of KES 50 million, at least 250 shareholders, total assets of at least KES 1 billion unless the Capital Markets Authority grants an exemption, and at least 15% public float, with a 24-month lock-in for controlling shareholders after listing.

The Growth Enterprise Market Segment (GEMS) is the more realistic route for a growth-stage company, dropping the profitability, dividend history and net asset requirements that make MIMS impractical for a younger business. An issuer needs paid-up share capital of KES 10 million, at least 100,000 shares in issue, a 15% float held by at least 25 shareholders within three months of listing, five directors with one third non-executive, and a mandatory nominated adviser. Our article on NSE Growth Board listing for health-tech companies looks at this pathway further. Even on GEMS, an IPO is slower and costlier than a trade sale, given prospectus preparation, CMA approval, and ongoing disclosure duties.

Secondary Sale and Share Buyback: Contractual and Companies Act Mechanics

A secondary sale to another private equity or venture fund, and a share buyback by the company or founders, are common exits when a trade sale or IPO is not available on the desired timeline. Kenyan shareholders’ agreements typically give existing shareholders a right of first refusal or pre-emption right before shares go to an outside buyer, so a secondary sale usually has to clear that mechanism first.

Where the exit is a buyback, the Companies Act, 2015 governs. Sections 447 to 450 give a limited company the general power to purchase its own shares, subject to authorisation in the articles and approval of the contract terms. A private company has an option not available to public companies: sections 467 to 474 allow it to fund the purchase out of capital, subject to a directors’ solvency statement, an auditor’s report confirming that opinion, and a special resolution, with dissenting shareholders able to apply to court to cancel the payment. Where the exit instead proceeds by capital reduction, sections 407 and 419 to 420 allow a private company to reduce share capital by special resolution supported by a solvency statement, avoiding the court process a public company needs.

Tax and Exchange Control on Exit Proceeds

Capital gains on a Kenyan exit are generally taxed at 15%, the rate applying since the Finance Act 2022 took effect on 1 January 2023, up from 5% previously. This is a final tax under the Income Tax Act’s Eighth Schedule, applying to residents and non-residents alike, and non-residents disposing of a significant shareholding are within scope under rules KRA has applied since mid-2023. A deferred consideration or earn-out structured as ordinary income can attract withholding tax rather than CGT treatment, so the sale agreement should characterise consideration carefully.

A non-resident repatriating proceeds works through an authorised dealer bank rather than directly with the Central Bank of Kenya (CBK). CBK’s Guidelines on Foreign Exchange require dealer banks to hold documentation before processing repatriation, including audited financials, the directors’ resolution declaring any dividend, a certified shareholder list, and evidence withholding tax has been paid. Banks must report foreign exchange payments of USD 100,000 or more to CBK’s Financial Markets Department the next working day. There is no general requirement for prior CBK approval, but the documentation trail needs building before completion.